Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: Prognostic factors and unique toxicity profile

Yutaka Hattori, Shin Ichiro Okamoto, Naoki Shimada, Tsunayuki Kakimoto, Kunihiko Morita, Yusuke Tanigawara, Yasuo Ikeda

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Fingerprint Dive into the research topics of 'Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: Prognostic factors and unique toxicity profile'. Together they form a unique fingerprint.

Medicine & Life Sciences